StockWatch
·

BOSTON SCIENTIFIC CORP Q1 FY26 Results

BSXQ1 FY26 Results
Filing
MetricValue ($ M)Q1 FY25
Revenue5.2K11.6%
Total Income5.2K11.6%
Expenditure4.1K9.6%
PBT1.2K44.4%
Net Profit1.3K99.0%
OPM21.16%1.41pp
NPM25.77%11.32pp
EPS0.9095.7%
View full financials

Boston Scientific Reports Q1 2026 Net Sales of $5.203 Billion, Up 11.6%

22 Apr 2026 · 22 Apr, 4:04 pm

Summary

Boston Scientific reported net sales of $5.203 billion for the first quarter of 2026, representing an 11.6 percent increase on a reported basis. GAAP net income attributable to common stockholders was $1.341 billion, or $0.90 per share. Adjusted EPS for the quarter was $0.80 per share. The company is now estimating full year 2026 net sales growth of approximately 7.0 to 8.5 percent on a reported basis and adjusted EPS of $3.34 to $3.41.

Key Highlights

  1. 1

    Boston Scientific generated net sales of $5.203 billion during the first quarter of 2026, an increase of 11.6 percent on a reported basis compared to the prior year period.

  2. 2

    GAAP net income attributable to Boston Scientific common stockholders was $1.341 billion, or $0.90 per share, compared to $674 million, or $0.45 per share, a year ago.

  3. 3

    Adjusted EPS for the first quarter was $0.80 per share, compared to $0.75 per share in the prior year.

  4. 4

    Cardiovascular net sales grew by 13.5 percent reported and 11.2 percent on an operational and organic basis compared to the prior year period.

  5. 5

    Net sales in the Asia-Pacific region increased by 14.7 percent reported and 12.0 percent operational compared to the prior year period.

  6. 6

    The company now estimates net sales growth for the full year 2026 to be approximately 7.0 to 8.5 percent on a reported basis.

  7. 7

    The company estimates adjusted EPS for the full year 2026 to be $3.34 to $3.41.

Management Comments

M

Mike Mahoney

Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter. We remain focused on executing our long-term strategy and advancing our differentiated pipeline to drive meaningful impact for patients, physicians and hospital systems.

Informational and educational content only. Not investment advice.